Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 10Terminated 7Recruiting 6Active not recruiting 4Unknown 2Not yet recruiting 1

Sponsor Class

OTHER 10INDUSTRY 2UNKNOWN 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gynecologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Injections 54Cisplatin 49Paclitaxel 48Carboplatin 43Gemcitabine 38pembrolizumab 36Docetaxel 36Capecitabine 36Drug Therapy 34anlotinib 25Bevacizumab 25Fluorouracil 24Cyclophosphamide 24icotinib 23Oxaliplatin 20fludarabine 19Pemetrexed 17Leucovorin 16Irinotecan 16Temozolomide 14Nivolumab 14Doxorubicin 14Cetuximab 14camrelizumab 13apatinib 13Trastuzumab 12Rituximab 11Fulvestrant 11Etoposide 11tesetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × 1-dodecylpyridoxal × Clear all
NCT04983550 2021-07-30

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Unknown
126 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03419494 2018-02-05

Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown
40 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡